Skip to content

Kodiak Sciences Inc KOD Net Investment in Lease

Net Investment in Lease at other companies

HRO
HarrowHROW
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Ocular Therapeutix logo
Ocular TherapeutixOCUL
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's net investment in lease?
Kodiak Sciences Inc (KOD) reported net investment in lease of $34.38M in Q1 2026.
How has Kodiak Sciences Inc's net investment in lease changed year-over-year?
Kodiak Sciences Inc's net investment in lease decreased by 19.1% year-over-year, from $42.47M to $34.38M.
What is the long-term trend for Kodiak Sciences Inc's net investment in lease?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's net investment in lease has grown at a -13.1% compound annual growth rate (CAGR), from $73.67M to $36.61M.